年销4亿大单品构筑护城河 中健康桥深耕慢性病赛道谋求综合性跨越

Core Viewpoint - The listing process of Zhongjian Health Bridge Pharmaceutical Group Co., Ltd. is at a critical juncture, highlighting the company's focus on chronic disease management, particularly in cardiovascular medications, as it seeks to leverage capital market opportunities for growth [1][4]. Group 1: Company Overview - Zhongjian Health Bridge is a modern comprehensive pharmaceutical enterprise that focuses on the chronic disease sector, with a core emphasis on cardiovascular medications [1]. - The company has successfully identified and addressed clinical pain points, particularly the gastrointestinal side effects associated with traditional aspirin, by launching its core product, aluminum magnesium aspirin tablets (II) [3]. Group 2: Product Development and Market Position - The aluminum magnesium aspirin tablets (II) is not merely a generic product; it combines aspirin with magnesium carbonate and aluminum hydroxide to reduce gastrointestinal adverse effects while maintaining antiplatelet efficacy [3]. - This product has achieved significant sales growth, with revenue surpassing 400 million yuan in 2024, and it has established a strong market presence across over 12,000 terminals [3]. Group 3: Financial Performance - From 2022 to 2024, the company's revenue increased from 268 million yuan to 447 million yuan, with a gross margin consistently above 90%, reaching 92.66% in 2024 [4]. - The net profit attributable to the parent company reached 103 million yuan in 2024, with net cash flow from operating activities at 111 million yuan, indicating strong profitability and cash flow alignment [4]. Group 4: Growth Strategy - Zhongjian Health Bridge is not solely reliant on its flagship product; it is pursuing a dual strategy of "R&D + M&A" to build a diversified product portfolio and mitigate risks [4]. - The company has successfully acquired drug registration certificates and related technologies for hydrochloride alprostadil tablets and sodium fusidate for injection, enhancing its product offerings in hypertension and infection treatment [4]. Group 5: Research and Development - The company maintains a long-term commitment to independent research and development, with established technology centers in Xi'an and Linyi [5]. - Currently, Zhongjian Health Bridge has five core technology platforms and is developing one class 1 new drug and six class 2 new drugs, including a significant product in the anti-epileptic field, sodium valproate sustained-release tablets [5]. Group 6: Future Outlook - The upcoming listing on the Beijing Stock Exchange represents a pivotal moment for Zhongjian Health Bridge as it transitions from a single-product focus to a modern comprehensive pharmaceutical group [5]. - The feedback from the second round of inquiries will provide clearer insights into how the company plans to utilize capital market resources to expand capacity and accelerate R&D in the growing chronic disease management sector [5].